Janssen to Make Several INVOKANA Presentations at EASD Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steadies as US fuel demand concerns face Middle East supply risks
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Janssen to Present Data from Nine Abstracts on INVOKANA® (canagliflozin) at 2016 European Association for the Study of Diabetes Annual Meeting
September 9, 2016 2:30 AM EDTRARITAN, N.J., Sept. 9, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that nine presentations on INVOKANA® (canagliflozin) will be featured at the 2016 European Association for the Study of Diabetes (EASD) Annual Meeting, September 12-16 in Munich, Germany. Presentation topics include:
Clinical findings showing INVOKANA® slows progression of renal function decline independent of glycaemic effects Clinical findings on the effects of INVOKANA® in combination with phentermine on weight management in overweight and obese adults New real-world findings on the correlation between absenteeism and productivity at work... More
